SPC230

Kladribín

  • Status:
    Afskrifuð
  • Application date:
    16.7.2018
  • Application published:
    15.8.2018
  • Grant published:
    15.7.2020
  • Max expiry date:
    19.12.2030
  • Medicine name:
    Mavenclad
  • Medicine for children:
    No

Timeline

Today
16.7.2018Application
15.8.2018Publication
15.7.2020Registration
19.12.2030Expires

Marketing license

  • IS authorization number:
    EU/1/17/1212/001-006
  • Date:
    13.9.2017
  • Foreign authorization number:
    EU/1/17/1212
  • Date:
    22.8.2017

Owner

  • Name:
    Merck Serono SA
  • Address:
    Centre Industriel, Coinsins, Vaud CH

Agent

  • Name:
    Árnason Faktor ehf.
  • Address:
    Guðríðarstíg 2-4, 113 Reykjavík

Patent

Upload documents